Patient characteristics
| . | N = 345 . | % . |
|---|---|---|
| Age median (range), y | 50.2 (0.7-70.5) | |
| Sex | ||
| Female | 174 | 50.4 |
| Male | 171 | 49.6 |
| Disease | ||
| AML | 186 | 53.9 |
| MDS | 106 | 30.7 |
| ALL | 36 | 10.4 |
| Others∗ | 17 | 4.9 |
| Donor type | ||
| Matched URD | 128 | 37.1 |
| MRD | 85 | 24.6 |
| CB | 120 | 34.8 |
| Mismatched URD | 12 | 3.5 |
| Graft source | ||
| PBSC | 199 | 57.7 |
| CB | 120 | 34.8 |
| BM | 26 | 7.5 |
| GVHD prophylaxis | ||
| CNI + MMF ± other | 221 | 64.8 |
| CNI + MTX ± other | 120 | 35.2 |
| Recipient CMV | ||
| Seropositive | 225 | 65.2 |
| Seronegative | 113 | 32.8 |
| Missing | 7 | 2.0 |
| ABO | ||
| Matched | 127 | 54.0 |
| Major mismatch | 43 | 18.3 |
| Minor mismatch | 51 | 21.7 |
| Bidirectional mismatch | 14 | 6.0 |
| Race | ||
| White | 272 | 78.8 |
| Asian | 37 | 10.7 |
| Other† | 36 | 10.4 |
| Ethnicity | ||
| Not Hispanic or Latino | 318 | 92.2 |
| Hispanic or Latino | 22 | 6.4 |
| Unknown | 5 | 1.4 |
| Follow-up among survivors, median (range), mo | 64.6 (12-165.7) |
| . | N = 345 . | % . |
|---|---|---|
| Age median (range), y | 50.2 (0.7-70.5) | |
| Sex | ||
| Female | 174 | 50.4 |
| Male | 171 | 49.6 |
| Disease | ||
| AML | 186 | 53.9 |
| MDS | 106 | 30.7 |
| ALL | 36 | 10.4 |
| Others∗ | 17 | 4.9 |
| Donor type | ||
| Matched URD | 128 | 37.1 |
| MRD | 85 | 24.6 |
| CB | 120 | 34.8 |
| Mismatched URD | 12 | 3.5 |
| Graft source | ||
| PBSC | 199 | 57.7 |
| CB | 120 | 34.8 |
| BM | 26 | 7.5 |
| GVHD prophylaxis | ||
| CNI + MMF ± other | 221 | 64.8 |
| CNI + MTX ± other | 120 | 35.2 |
| Recipient CMV | ||
| Seropositive | 225 | 65.2 |
| Seronegative | 113 | 32.8 |
| Missing | 7 | 2.0 |
| ABO | ||
| Matched | 127 | 54.0 |
| Major mismatch | 43 | 18.3 |
| Minor mismatch | 51 | 21.7 |
| Bidirectional mismatch | 14 | 6.0 |
| Race | ||
| White | 272 | 78.8 |
| Asian | 37 | 10.7 |
| Other† | 36 | 10.4 |
| Ethnicity | ||
| Not Hispanic or Latino | 318 | 92.2 |
| Hispanic or Latino | 22 | 6.4 |
| Unknown | 5 | 1.4 |
| Follow-up among survivors, median (range), mo | 64.6 (12-165.7) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CB, cord blood; CMV, cytomegalovirus; CNI, calcineurin inhibitor; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MTX, methotrexate; PBSC, peripheral blood stem cell.
Other: biphenotypic acute leukemia (n = 2), chronic lymphocytic leukemia (n = 1), chronic myeloid leukemia (n = 2), chronic myelomonocytic leukemia (n = 7), leukemia, not otherwise specific (n = 1), myeloproliferative disorder (n = 3), and non-Hodgkin lymphoma (n = 1).
Other: Black or African American (n = 7), American Indian or Alaska Native (n = 7), Native Hawaiian or other Pacific Islander (n = 9), multiple (n = 3), and unknown (n = 10).